Cargando…
A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations
With advancement of technologies such as genomic sequencing, predictive biomarkers have become a useful tool for the development of personalized medicine. Predictive biomarkers can be used to select subsets of patients, which are most likely to benefit from a treatment. A number of approaches for su...
Autores principales: | Huber, Cynthia, Benda, Norbert, Friede, Tim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772173/ https://www.ncbi.nlm.nih.gov/pubmed/31270933 http://dx.doi.org/10.1002/pst.1951 |
Ejemplares similares
-
On estimands and the analysis of adverse events in the presence of varying follow‐up times within the benefit assessment of therapies
por: Unkel, Steffen, et al.
Publicado: (2018) -
Blinded continuous monitoring in clinical trials with recurrent event endpoints
por: Friede, Tim, et al.
Publicado: (2018) -
Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data
por: Kunz, Cornelia Ursula, et al.
Publicado: (2014) -
Dose‐escalation strategies which use subgroup information
por: Cotterill, Amy, et al.
Publicado: (2018) -
A critical review of graphics for subgroup analyses in clinical trials
por: Ballarini, Nicolás M., et al.
Publicado: (2020)